Studio di PIT565 nelle neoplasie a cellule B recidivanti e/o refrattarie
Uno studio multicentrico di fase I, in aperto, su PIT565 in pazienti con neoplasie a cellule B recidivanti e/o refrattarie
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is an open-label, multicenter, phase I study of PIT565 in patients with R/R B-NHL and R/R B-ALL.
The study comprises a dose escalation part of PIT565 in two independent groups (group A: R/R B-NHL and B: R/R B-ALL) and a dose expansion part in three independent groups (R/R large B-cell lymphoma (LBCL) randomized in 1:1 ratio to two RDs (A1 and A2), and R/R B-ALL (B1)).
During the dose escalation, the safety (including the dose-dose limiting toxicity (DLT) relationship) and tolerability of PIT565 will be assessed, and schedule(s), route(s) of administration and dose(s) will be identified for use in the expansion part based on the review of these data. The RD will also be guided by the available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity. The dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the Escalation with Overdose Control (EWOC) principle.
Different schedules and routes of administrations will be explored in the dose escalation groups.
The dose expansion will further explore the MTD(s) and/or RD(s) and the selected schedule(s) and route of administration(s) in the three patients' groups.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Ghent, Belgio, 9000
- Novartis Investigative Site
-
-
-
-
-
Beijing, Cina, 100730
- Novartis Investigative Site
-
Shanghai, Cina, 200032
- Novartis Investigative Site
-
Tianjin, Cina, 300020
- Novartis Investigative Site
-
-
-
-
-
Créteil, Francia, 94010
- Novartis Investigative Site
-
Marseille, Francia, 13273
- Novartis Investigative Site
-
-
-
-
Chiba
-
Kashiwa, Chiba, Giappone, 2778577
- Novartis Investigative Site
-
-
-
-
-
Tel Aviv, Israele, 6423906
- Novartis Investigative Site
-
-
-
-
RE
-
Reggio Emilia, RE, Italia, 42123
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 119074
- Novartis Investigative Site
-
Singapore, Singapore, 169608
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spagna, 08035
- Novartis Investigative Site
-
Barcelona, Spagna, 08036
- Novartis Investigative Site
-
-
-
-
Florida
-
Miami, Florida, Stati Uniti, 33136
- University Of Miami
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Medical Center
-
-
Kansas
-
Fairway, Kansas, Stati Uniti, 66205
- The University of Kansas Clinical Research Ctr
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Ctr
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health Sciences University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Male or female patients ≥18 years of age at the date of signing the informed consent form
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2
NHL patient population
- Refractory or relapsed B-NHL
- Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen
- Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan
ALL patient population
- Refractory or relapsed CD19-positive B-ALL
- Morphologic disease in the bone marrow (≥ 5% blasts)
Exclusion Criteria:
- History of severe hypersensitivity to any ingredient of the study treatment or its excipients
- Contraindication to tocilizumab
- History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
- Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
- Active central nervous system (CNS) involvement by malignancy or presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within the 2 weeks prior to the start of study treatment
- Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
- Patients receiving systemic treatment with any immunosuppressive medication
Other protocol-defined inclusion/exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: PIT565 Group A (dose escalation part)
PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Sperimentale: PIT565 Group B (dose escalation part)
PIT565 in adult R/R ALL patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Sperimentale: PIT565 Group A1 (dose expansion part)
PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Sperimentale: PIT565 Group A2 (dose expansion part)
PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
|
Sperimentale: PIT565 Group B1 (dose expansion part)
PIT565 in adult R/R ALL patients. |
Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and severity of Dose Limiting Toxicities (DLTs)
Lasso di tempo: 28 days or 35 days, depending on the dosing schedule
|
Assessment of safety of study drug. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of CTCAE grade 3 or higher that occurs within the DLT evaluation period (28 days or 35 days depending on the schedule) and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with exceptions provided in the clinical protocol. |
28 days or 35 days, depending on the dosing schedule
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: 21 months
|
Assessment of safety of study drug. |
21 months
|
|
Frequency of dose interruptions
Lasso di tempo: 21 months
|
Assessment of tolerability of study drug |
21 months
|
|
Frequency of dose reductions
Lasso di tempo: 21 months
|
Assessment of tolerability of study drug |
21 months
|
|
Dose intensities
Lasso di tempo: 21 months
|
Assessment of tolerability of study drug Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of exposure. |
21 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Response Rate (ORR)
Lasso di tempo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Complete Response (CR) rate
Lasso di tempo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Best Overall Response (BOR)
Lasso di tempo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Duration Of Response (DOR)
Lasso di tempo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Overall Survival (OS)
Lasso di tempo: 33 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification and anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
33 months
|
|
Progression Free Survival (PFS)
Lasso di tempo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Non-Hodgkin Lymphoma will be based on the Lugano Response Criteria Classification Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Event-free survival (EFS)
Lasso di tempo: 21 months
|
Evaluation of anti-tumor activity of PIT565 for Acute Lymphoblastic Leukemia will be based on National Comprehensive Cancer Network (NCCN) 2018 v1 guidelines. Local investigator assessment will be used for analysis of efficacy endpoints. |
21 months
|
|
Maximum concentration of PIT565 (Cmax)
Lasso di tempo: 21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Area Under the Curve of PIT565 (AUC)
Lasso di tempo: 21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Trough concentration of PIT565 (C trough)
Lasso di tempo: 21 months
|
Pharmacokinetics (PK) parameters will be determined using non-compartmental method(s) |
21 months
|
|
Prevalence of Anti-drug antibodies (ADA) at baseline
Lasso di tempo: Baseline
|
Assessment of anti-PIT565 antibodies in serum. |
Baseline
|
|
Incidence of Anti-drug antibodies (ADA) on treatment
Lasso di tempo: 21 months
|
Assessment of anti-PIT565 antibodies in serum. |
21 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Infezioni
- Malattie virali
- Neoplasie per tipo istologico
- Malattie ematologiche
- Infezioni da virus del DNA
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma
- Leucemia, linfoide
- Leucemia
- Infezioni da virus di Epstein-Barr
- Infezioni da Herpesviridae
- Infezioni da virus tumorali
- Malattie emiche e linfatiche
- Linfoma, cellule B
- Leucemia-linfoma linfoblastico a cellule precursori
- Linfoma di Burkitt
- Linfoma non Hodgkin
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CPIT565A12101
- 2022-000367-45 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .